Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | ELANE | P08246 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | APLNR | P35414 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3025615 | 0.85 | MAPT (0.46) | KMT2AMAPTSMN1; SMN2ELANEMEN1 | |
| SCHEMBL942730 | 0.79 | ELANE (0.57) | KMT2AMAPTSMN1; SMN2ELANEALDH1A1 | |
| SCHEMBL3030393 | 0.77 | CA12 (0.44) | KMT2AMAPTSMN1; SMN2CA12CA9 | |
| SCHEMBL10328549 | 0.75 | CYP1A2 (0.44) | KMT2AMAPTSMN1; SMN2ELANEMEN1 | |
| SCHEMBL30450771 | 0.73 | KMT2A (0.46) | KMT2AMAPTSMN1; SMN2CA12CA9 | |
| SCHEMBL9644263 | 0.71 | KMT2A (1.00) | KMT2AMAPTSMN1; SMN2CA12CA9 | |
| SCHEMBL9721396 | 0.71 | SMN1; SMN2 (0.63) | KMT2AMAPTSMN1; SMN2CA12CA9 | |
| SCHEMBL17196170 | 0.70 | SMN1; SMN2 (0.35) | KMT2AMAPTSMN1; SMN2ELANEALDH1A1 | |
| SCHEMBL725404 | 0.70 | KMT2A (0.76) | KMT2AMAPTSMN1; SMN2CA12CA9 | |
| SCHEMBL6766253 | 0.70 | TSHR (0.63) | KMT2AMAPTSMN1; SMN2SLC6A3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183398-B2 | 5-hydroxy-2-methyl-4H-pyran-4-one esters as novel tyrosinase inhibitors | EASTMAN CHEMICAL COMPANY (US) | 2012-05-22 | — | — | US | disclosed |
| EP-2245024-A1 | 5-HYDROXY-2-METHYL-4H-PYRAN-4-ONE-ESTERS AS NOVEL TYROSINASE INHIBITORS | Eastman Chemical Company (US) | 2010-11-03 | — | — | EP | disclosed |
| US-20100216873-A1 | 5-Hydroxy-2-Methyl-4H-Pyran-4-One Esters as Novel Tyrosinase Inhibitors | EASTMAN CHEMICAL COMPANY (US) | 2010-08-26 | — | — | US | disclosed |
| WO-2009108272-A1 | 5-HYDROXY-2-METHYL-4H-PYRAN-4-ONE-ESTERS AS NOVEL TYROSINASE INHIBITORS | EASTMAN CHEMICAL COMPANY (US) | 2009-09-03 | — | — | WO | disclosed |
| US-20090215887-A1 | 5-HYDROXY-2-METHYL-4H-PYRAN-4-ONE ESTERS AS NOVEL TYROSINASE INHIBITORS | EASTMAN CHEMICAL COMPANY (US) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215887-A1 | 5-HYDROXY-2-METHYL-4H-PYRAN-4-ONE ESTERS AS NOVEL TYROSINASE INHIBITORS | TYR, CYP51A1, TH | KMT2A 667/4885MAPT 2600/4885SMN1; SMN2 4332/4885 |
| US-20100216873-A1 | 5-Hydroxy-2-Methyl-4H-Pyran-4-One Esters as Novel Tyrosinase Inhibitors | TYR, CYP51A1, TH | KMT2A 667/4885MAPT 2600/4885SMN1; SMN2 4332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.